A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa

Inclusion Criteria: * HIV-negative * Willing to participate and sign an informed consent form * Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group. * Willing to use two forms of contraception during the study * Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study. * Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses Exclusion Criteria: * Currently pregnant or breast-feeding * Clinically detectable genital abnormality on the vulva, vaginal walls or cervix * Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed GUD or active HSV-2 lesion * Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization * Symptomatic bacterial vaginosis at Screening and unwilling to undergo treatment. * Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.